Low Risk of Hyperprogression with First-Line
Chemoimmunotherapy for Advanced Non-Small Cell
Lung Cancer: Pooled Analysis of 7 Clinical Trials
Lee X. Li, Federico Cappuzzo, Ignacio Matos, Mark A. Socinski,
Ashley M. Hopkins, Michael J. Sorich
To read the article follow the link below:
LOW RISK OF HYPERPROGRESSION WITH FIRST LINE CHEMOIMMUNOTHERAPY FOR ADVANCED NSCLC
.pdf
Download PDF • 492KB